The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Hatch/Klobucher Introduce Orphan Exclusivity Bill in Senate To Bring House “Cures” Incentive Into Play May. 22, 2015
- House Opioid Hearing Highlights State Requirements for Prescriber Education, PDMP Participation May. 22, 2015
- “Breakthrough” Dose-Finding In Oncology: Enrollment A Plus, Speed To Commercialize An Impediment May. 21, 2015
See More Research Notes